Cite
HARVARD Citation
Martens, U. et al. (n.d.). 2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC). European journal of cancer. pp. S344-S345. [Online].